Regeneron Pharmaceuticals Aktie
WKN: 881535 / ISIN: US75886F1075
26.08.2024 13:45:00
|
Regeneron Pharma: European Commission Approves Ordspono - Quick Facts
(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) announced the European Commission has approved Ordspono or odronextamab to treat adult patients with relapsed or refractory follicular lymphoma or R/R diffuse large B-cell lymphoma, after two or more lines of systemic therapy. This marks the first regulatory approval of Ordspono. Ordspono is a bispecific antibody that acts by linking the lymphoma cell to a killer T cell.
The company said the approval is based on results from the Phase 1 ELM-1 and pivotal Phase 2 ELM-2 trials, which demonstrated robust, durable response rates in adults with R/R FL or R/R DLBCL.
For More Such Health News, visit rttnews.com.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Regeneron Pharmaceuticals Inc.mehr Nachrichten
Analysen zu Regeneron Pharmaceuticals Inc.mehr Analysen
Aktien in diesem Artikel
Regeneron Pharmaceuticals Inc. | 524,00 | -5,59% |
|